Transplacental Transfer of Maternal Antibody against SARS-CoV-2 and Its Influencing Factors: A Review

Liu, Shuang; Zhang, Dingmei

doi:10.3390/vaccines10071083

Cited by 15 publications

(17 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The degree of maternal protection through placental antibody transfer is most likely dependent on the maternal antibody concentration. In some studies, transplacental transfer of antibodies begins in the second trimester although it was more efficient in the third trimester [44].…”

Section: Preventionmentioning

confidence: 99%

Respiratory perspective of COVID-19 in pregnancy

Purwono

Agustin²,

Lisnawati³

et al. 2023

J Infect Dev Ctries

View full text Add to dashboard Cite

The coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was declared a global pandemic in March 2020 by the World Health Organization (WHO). By February 2022, the disease had infected more than 500 million people globally. COVID-19 frequently manifests as pneumonia and mortality is mainly caused by acute respiratory distress syndrome (ARDS). Previous studies have reported that pregnant women are at a higher risk of SARS-CoV-2 infection and complications can happen due to alterations in the immune response, respiratory physiology, hypercoagulable state, and placental pathology. Clinicians face the challenge of selecting the proper treatment for pregnant patients with different physiological characteristics compared with the non-pregnant population. Furthermore, drug safety for both the patient and the fetus should also be considered. Efforts to prevent COVID-19, including prioritizing vaccination for pregnant women, are essential to break the chain of COVID-19 transmission in the pregnant population. This review aims to summarize the current literature regarding the effect of COVID-19 in pregnant women, its clinical manifestations, treatment, complications, and prevention.

show abstract

Section: Preventionmentioning

confidence: 99%

Respiratory perspective of COVID-19 in pregnancy

Purwono

Agustin²,

Lisnawati³

et al. 2023

J Infect Dev Ctries

View full text Add to dashboard Cite

show abstract

“…In addition, we also analyzed patients that received up to four doses, which allowed us to compare the different vaccination schemes. Previously published studies showed results regarding BNT162b2, mRNA1273, and Ad26.COV2.S [ 35 , 36 ]. Many countries in the world have limited access to these types of vaccines.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of Transplacental Antibody Transfer in Pregnant Women Immunized with Different SARS-CoV-2 Homologous or Heterologous Schemes

Romero-Ibarguengoitia

Flores-Salazar

Arroyo-García

et al. 2023

Vaccines

View full text Add to dashboard Cite

There is scarce information related to transplacental antibody transfer against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with different homologous and heterologous vaccination schemes. This study aimed to correlate the magnitude of transplacental transfer anti-SARS-CoV-2 antibodies in different homologous and heterologous schemes. An observational cross-sectional study was developed to identify pregnant women vaccinated against SARS-CoV-2. They were questioned about their immunization status; blood samples from the mother, umbilical cord during labor, and the newborn 72 h after birth were taken to measure anti-S1 and anti-S2 specific IgG antibodies for SARS-CoV-2. We recruited 104 women with a median age of 29 (SD 1.17). We found antibodies in all newborns with vaccinated mothers. Homologous BNT162b2 mRNA regimen had the highest mean (SD) antibody titers (AU/mL) in maternal (994.93 (3.08), p = 0.039), umbilical cord (1316.43 (2.79), p = 0.016), and newborn (1192.02 (3.55), p = 0.020) blood. The generalized linear model showed a positive effect over antibodies with at least one dose in maternal (β = −1.1, p = 0.002) and newborn (β= −0.717, p = 0.044) blood, and with two doses (β = −0.684, p = 0.026) in umbilical cord blood. In conclusion, antibodies were detected in all vaccinated women and their newborns. Transfer of antibodies was found from the first dose, and the levels increased with the number of vaccine doses. Vaccination should be encouraged in pregnant women with any available scheme.

show abstract

“…Whether this effect could also be achieved with the mRNA vaccine or not is yet to be shown. However, it appears plausible since mRNA vaccination of pregnant women against COVID‐19 has been shown to lead to transplacental transfer of neutralizing antibodies (but no transfer of mRNA vaccine compounds) protecting SARS‐CoV‐2 during early infancy 205,206 …”

Section: Clinical Progress Of Mrna Candidates Beyond Covid‐19mentioning

confidence: 99%

mRNA vaccines: The future of prevention of viral infections?

Rzymski

Szuster‐Ciesielska

Dzieciątkowski

et al. 2023

Journal of Medical Virology

View full text Add to dashboard Cite

Messenger RNA (mRNA) vaccines against COVID-19 are the first authorized biological preparations developed using this platform. During the pandemic, their administration has been proven to be a life-saving intervention. Here, we review the main advantages of using mRNA vaccines, identify further technological challenges to be met during the development of the mRNA platform, and provide an update on the clinical progress on leading mRNA vaccine candidates against different viruses that include influenza viruses, human immunodeficiency virus 1, respiratory syncytial virus, Nipah virus, Zika virus, human cytomegalovirus, and Epstein-Barr virus. The prospects and challenges of manufacturing mRNA vaccines in low-income countries are also discussed. The ongoing interest and research in mRNA technology are likely to overcome some existing challenges for this technology (e.g., related to storage conditions and immunogenicity of some components of lipid nanoparticles) and enhance the portfolio of vaccines against diseases for which classical formulations are already authorized. It may also open novel pathways of protection against infections and their consequences for which no safe and efficient immunization methods are currently available.

show abstract

Transplacental Transfer of Maternal Antibody against SARS-CoV-2 and Its Influencing Factors: A Review

Cited by 15 publications

References 49 publications

Respiratory perspective of COVID-19 in pregnancy

Respiratory perspective of COVID-19 in pregnancy

Evaluation of Transplacental Antibody Transfer in Pregnant Women Immunized with Different SARS-CoV-2 Homologous or Heterologous Schemes

mRNA vaccines: The future of prevention of viral infections?

Contact Info

Product

Resources

About